

## In This Issue: January 3, 2023

## Research

## ORIGINAL INVESTIGATION

**28 Effect of Remifentanyl vs Neuromuscular Blockers During Rapid Sequence Intubation on Successful Intubation Without Major Complications Among Patients at Risk of Aspiration: A Randomized Clinical Trial**

N Grillo and Coauthors for the Atlanrea Study Group; Société Française d'Anesthésie Réanimation (SFAR) Research Network

This randomized trial assesses the effect of remifentanyl vs neuromuscular blockers on successful intubation without major complications among patients at risk of aspiration during rapid sequence intubation in the operating room.

**Visual Abstract**

**39 Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial**

Writing Committee for the REMAP-CAP Investigators

This secondary analysis of an ongoing adaptive platform trial examines the effect of multiple interventions for critically ill adults with COVID-19 on longer-term outcomes.

Editorial **25**

**52 Association of Race and Ethnicity With Initial Prescription of Antiretroviral Therapy Among People With HIV in the US**

LC Zalla and Coauthors

This retrospective observational study of adults entering HIV care between 2007 and 2019 compares differences in the prescription of integrase inhibitor-containing antiretroviral therapy by patient race and ethnicity.

Related Article **63**

## Opinion

## VIEWPOINT

**17 Medicaid, the Supreme Court, and Safe Care for Nursing Home Residents**

N Huberfeld

**19 Urgent Need for Next-Generation COVID-19 Vaccines**

PW Marks, PA Gruppiso, and EY Adashi

**Audio**

## A PIECE OF MY MIND

**21 The Scent of Hope**

B Redmond

In this narrative medicine essay, a neonatologist bends over her young daughter and breathes in the scent of hope after her child is hospitalized with diabetic ketoacidosis and a new diagnosis of diabetes.

## EDITORIAL

**23 Public Access to Scientific Research Findings and Principles of Biomedical Research—A New Policy for the JAMA Network**

K Bibbins-Domingo and Coauthors

**25 Long-term Follow-up After Critical COVID-19: REMAP-CAP Revisited**

ML Barnett and PE Sax

Related Article **39**

## Clinical Review &amp; Education

## SPECIAL COMMUNICATION

**63 Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society—USA Panel**

RT Gandhi and Coauthors

This guideline from the International Antiviral (formerly AIDS) Society—USA updates practice recommendations for managing HIV infection, including when to change antiretroviral regimens; use of preexposure prophylaxis to prevent infection in at-risk persons; care of pregnant persons with HIV, people aging with HIV, and people with substance use disorder and HIV; and new challenges in people with HIV, including COVID-19 and monkeypox virus infection.

**Audio**

## JAMA INSIGHTS

**85 RNA Sequencing as a Diagnostic Tool**

S Ketkar, LC Burrage, and B Lee

This JAMA Insights discusses RNA sequencing, which allows detection of qualitative and quantitative changes in RNA expression across the genome in clinical samples, and how it may improve molecular diagnostic rates achieved by diagnostic exome sequencing and whole-genome sequencing alone.

## Online at JAMA.com

## AUDIO

Editor's Summary of This Issue

December 2022 Medical News Summary

Urgent Need for Next Generation COVID-19 Vaccines

Advances in Treatment and Prevention of HIV

## CME

CME quizzes online at [jamacmelookup.com](http://jamacmelookup.com)

**CME Disclosure Statement:** Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

## INSTRUCTIONS FOR AUTHORS

[jamanetwork.com/pages/for-authors](http://jamanetwork.com/pages/for-authors)

## DEPARTMENTS

Staff Listing **5**

Recruitment & Classified Advertising **102**

Contact Information **103**



**Editor in Chief**  
Kirsten Bibbins-Domingo, PhD, MD, MAS

**Available online**

[jama.com](http://jama.com)



continued >



## In This Issue: January 3, 2023

## JAMA PATIENT PAGE

## 104 What Is Pulmonary Embolism?

K Walter

This JAMA Patient Page describes pulmonary embolism signs and symptoms, risk factors, diagnosis, and treatment options.

## News &amp; Analysis

## MEDICAL NEWS &amp; PERSPECTIVES

7 Cardiovascular Corner—  
Researchers Probe Factors  
That May Contribute  
to Cardiovascular Health Disparities

M Suran

This Medical News article highlights recently published research about disparities in cardiovascular health.

9 Amid Ohio Measles Outbreak, New Global  
Report Warns of Decreased Vaccination  
During COVID-19 Pandemic

J Abbasi

This Medical News article discusses an annual report on measles from the World Health Organization and the US Centers for Disease Control and Prevention.

 Audio

## NEWS FROM THE JAMA NETWORK

12 Mindfulness Noninferior to Medication  
for Quelling Anxiety12 Low-Dose Aspirin Does Not Appear  
to Reduce Fractures12 Vitamin C Improved Respiratory Health  
Among Children Born to Pregnant People  
Who Smoked13 Entirely Remote Intervention Decreased  
BP and LDL-C in Diverse Patient GroupsNEWS FROM THE FOOD AND DRUG  
ADMINISTRATION14 First FDA-Approved Gene Therapy  
for Hemophilia

## 14 New Drug Delays Type 1 Diabetes Onset

14 Combined COVID-19 and Flu Test  
Authorized for Point-of-Care Use

## Humanities

## POETRY AND MEDICINE

## 100 Maine Medical Center

D Ebenbach

## JAMA REVISITED

## 101 Present Status of "Insulin"

## Letters

## RESEARCH LETTER

87 Manufacturer Revenue on Inhalers  
After Expiration of Primary Patents,  
2000-2021

WB Feldman and Coauthors

This study quantifies the revenue earned on all brand-name inhalers approved by the US Food and Drug Administration from 2000 to 2021 and compared earnings before and after expiration of primary patents on these products.

89 Estimated Medicare Part B Savings  
From Inflationary Rebates

AC Egilman, AS Kesselheim, and BN Rome

This study uses annual Medicare Part B spending data to examine the potential savings from the drug pricing reforms in the Inflation Reduction Act of 2022.

92 COVID-19 and Excess All-Cause Mortality  
in the US and 20 Comparison Countries,  
June 2021-March 2022

A Bilinski, K Thompson, and E Emanuel

This study compares the COVID-19 per capita overall and excess mortality rates in the US vs rates for 20 Organization for Economic Co-operation and Development countries and the timing of any increases in excess mortality between June 2021 and December 2021 (Delta) and December 2021 to March 2022 (Omicron).

## COMMENT &amp; RESPONSE

Opportunities for Clinicians and Health  
Systems to Address Disparities in US Drug  
Overdose Deaths by Race and Ethnicity

94 M Kirkegaard and B Manuagh

## In Reply

95 M Kariisa, P Seth, and CM Jones

## Gout Flare and Cardiovascular Events

96 AC Fonseca

## In Reply


96 E Cipolletta, LJ Tata, and A Abhishek

High- vs Low-Dose Tranexamic Acid Infusion  
and Need for Red Blood Cell Transfusion  
and Adverse Events in Cardiac Surgery

97 A Koster, N Hulde, and A Zittermann

## In Reply

97 J Shi, C Zhou, and Z Zheng

 Available online